CAMK2G and memory impairment: Our present findings reveal that CaMKII is a relevant actor for the maintenance of CTA-LTM, since intracortical microinfusion of myr-CaMKIINtide 24 h after CTA acquisition lead to memory impairment during LTM aversion test, performed 72 h after CTA acquisition.